Kristina Jankovic, MD· @JankovicK · X·· 22 小时前评分70
正文 · 机器翻译
🎬 最新 @OncoAlert 🚨 来自 #ESMO26 🇪🇸 的 #Podium2Screen
@stolaney1 探讨了 #evERA 生物标志物分析：giredestrant + everolimus 在不同的 ctDNA 比例、ESR1 变异以及伴有 TP53、GATA3 或 RB1 改变的不良预后亚组中均维持了其 PFS 获益。
#BreastCancer
99 浏览 · 4 赞 · 1 转发 · 0 回复
🎬 New OncoAlert #Podium2Screen 🎬 from #ESMO26 Our #BreastCancer faculty member @stolaney1 🇺🇸(@DanaFarber) walks us through her #ESMO26 presentation: biomarker analyses from evERA @elmayermd, @stolaney1, @GregoryAVidal, @jhaveri_komal, @breastoncdoc, @DrWGradishar, @NaokiNiikura, @FavretMD, @DraAlfie, @hoperugo 🔹 Giredestrant + everolimus kept its PFS benefit regardless of ctDNA fraction 🔹 Benefit held across ESR1 variants, including Y537 (HR 0.35) 🔹 Benefit also held in poor-prognosis subgroups (TP53, GATA3, RB1) Pinging OncoAlert Breast Cancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76在 X 查看被引用的帖子
来源：Kristina Jankovic, MD · x.com